A study in 2005 tested in an experimental setup the efficiency of chloroquine to stop the coranavirus S spike from developing and to ace 2 enzyme thereby stopping transmission and cutting the infection time. However this was done in SARS-CoV infecting primate kidney cell lines. Does anyone have any literature or source if chloroquine is effective in preventing transmission and infections in humans against the 2019-nCoV and if so what would be best effective drug concentration to do so?
virologyj.biomedcentral.com/.../1743-422X-2-69
Also has anyone tested the efficiency of using ace 2 inhibitors to stop the transmission
This is a very interesting point, as chloroquine has also been shwon to inhibit replication of the MERS CoV in cell cultures. As far as I am aware there is so far no literature available on CQ and 2019-nCoV.
This is a very interesting point, as chloroquine has also been shwon to inhibit replication of the MERS CoV in cell cultures. As far as I am aware there is so far no literature available on CQ and 2019-nCoV.
It's really very interesting to know about this, actually it's novel one but no literally is available on this topic
It requires further studies
Chloroquine has a pleiotropic effect and could be helpful in this direction.
Very interesting point, the effectiveness of the drug may depend upon PH.
Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.
https://www.nature.com/articles/s41422-020-0282-0
In order for signalling from these TLRs to occur endosomal acidification and maturation are required, leading to the production of proinflammatory cytokines and type I interferons (IFNs) [6].
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962956/
Here is some literature published recently on treatment options for the 2019nCov
- https://www.nature.com/articles/s41422-020-0282-0
- http://www.ecns.cn/news/society/2020-01-30/detail-ifztewca0589338.shtml
apparently recent clinical data shows a combination of
Remdesivir, chloroquine and PI's such as Lopinavir/ritonavir have shown great promise in effectively treating patients. However with the R0 staying at a constant 2.5 and the mortality rate being 11% ( SARS has a mortality rate of 10%+ and MERS at 35%) *study attached below for refrence
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext
If the above drugs remain effective do you think a mass prophylaxis would be justified even if the mortality rate remains at 11% or do you think the risk of development of resistance is far more greater concern as it did with oseltamivir and influenza A
Also my sincere thanks to Prof. Christian G Meyer , Dr. Masato Hada , Dr . Emmanuel Ifeanyi Obeagu and Prof. Malangori Parande for thier answers and contributions to this thread.
- Badges
- Science topic
- Similar topics
- Medicine
- Public Health